Research Topics
| Robert J AmatoSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Thalidomide: an antineoplastic agentRobert J Amato
Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
Curr Oncol Rep 4:56-62. 2002..Current research on thalidomide in oncology covers investigation in a wide range of both solid tumors and hematologic malignancies...- Renal cell carcinoma: review of novel single-agent therapeutics and combination regimensR J Amato
The Methodist Hospital, Baylor College of Medicine, Scott Department of Urology, Section of Genitourinary Oncology, Houston, TX, USA
Ann Oncol 16:7-15. 2005..Based on preliminary and limited studies, combination therapies offer the greatest clinical benefit in the management of this malignancy, although additional basic research is still warranted... - Thalidomide therapy for renal cell carcinomaRobert J Amato
Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, 77030, Houston, TX, USA
Crit Rev Oncol Hematol 46:S59-65. 2003..To review the use of thalidomide as a therapeutic option for patients with metastatic renal cell carcinoma (RCC)... - Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trialRobert J Amato
The Methodist Hospital Research Institute, Houston, Texas 77030, USA
Clin Cancer Res 14:7504-10. 2008..The safety, immunologic, and clinical efficacy of TroVax in combination with IL-2 was determined... - Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trialRobert J Amato
Memorial Hermann Cancer Center, The University of Texas Health Science Center, Houston, TX 77030, USA
J Immunother 32:765-72. 2009..Despite the high frequency of 5T4-specific immune responses, it is not possible to conclude that patients are receiving clinical benefit. The results are encouraging and warrant further investigation... - Lenalidomide therapy for metastatic renal cell carcinomaRobert J Amato
Genitourinary Oncology Program, Methodist Hospital Research Institute, Houston, TX 77030, USA
Am J Clin Oncol 31:244-9. 2008..Oral lenalidomide, a thalidomide-based drug having enhanced immunomodulatory and antiangiogenic properties and reduced toxicity, was evaluated for safety and efficacy in this setting... - Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancerRobert J Amato
The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050 Houston, TX 77030, USA
J Exp Ther Oncol 7:41-7. 2008..A prospective investigation of this combination warranted... - Pilot study of rapamycin in patients with hormone-refractory prostate cancerRobert J Amato
University of Texas Health Science Center, Memorial Hermann Hospital, Houston, TX 77030, USA
Clin Genitourin Cancer 6:97-102. 2008..Rapamycin, an immunosuppressive macrolide, inhibits metastatic prostate tumor growth and angiogenesis in in vivo mouse models. This pilot study assessed the antitumor activity, safety, and toxicity of rapamycin in patients with HRPC... - Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinomaRobert J Amato
Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050, Houston, TX 77030, USA
Am J Clin Oncol 31:237-43. 2008..This study assessed whether GM-CSF would improve the response rate of MRCC patients to the thalidomide plus IL-2 regimen... - Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancerRobert J Amato
The Methodist Hospital, The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, TX 77030, USA
Am J Clin Oncol 31:532-8. 2008..This phase II study investigated the addition of Sr-89 to an alternating weekly regimen of doxorubicin and ketoconazole with paclitaxel and estramustine in patients with progressive prostate cancer and bone involvement... - Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancerMichael T Tetzlaff
Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, ST 2100, Houston, Texas 77030, USA
Technol Cancer Res Treat 5:23-36. 2006..The combined approach maximizes tumor control, both local-regional and systemic through radio-genetherapy induced cytotoxicity and anti-tumor immunity... - Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostateRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
Urol Oncol 27:8-13. 2009.... - A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinomaRobert J Amato
The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050, Houston, TX 77030, USA
Cancer Chemother Pharmacol 61:1069-73. 2008..We have conducted a phase I trial to determine the maximum tolerated dose of gemcitabine in combination with interferon, thalidomide and capecitabine... - A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostateRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
Urol Oncol 27:165-9. 2009..A retrospective review was conducted to evaluate results... - Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot studyRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital, Research Institute, Houston, TX 77030, USA
Invest New Drugs 24:171-5. 2006..To assess the activity and toxicity of interferon-alpha (IFN-alpha), capecitabine, and thalidomide in patients with metastatic renal cell carcinoma (MRCC)... - Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinomaRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
Cancer 106:1498-506. 2006..The purpose of the study was to determine, in a Phase I/II study, the efficacy and safety profile of thalidomide with interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC)... - Current immunotherapeutic strategies in renal cell carcinomaRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, 6560 Fannin, Houston, TX 77030, USA
Surg Oncol Clin N Am 16:975-86, xi-xii. 2007..An additional approved tyrosine kinase inhibitor, sorafenib, is recommended as second-line therapy. More clinical research on these agents and their use in combination, especially sequentially, is warranted... - Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study resultsRobert J Amato
Department of Internal Medicine, Division of Oncology, The University of Texas Health Science Center, Memorial Hermann Hospital, Houston, TX 77030, USA
Clin Genitourin Cancer 6:73-8. 2008..We evaluated the safety and efficacy of motexafin gadolinium (MGd), a Trx inhibitor, as a single-agent therapy for metastatic RCC... - 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapyRobert J Amato
The University of Texas Medical School at Houston, Memorial Hermann Cancer Center, 6410 Fannin, Suite 710, Houston 77030, TX, USA
Expert Opin Biol Ther 10:281-7. 2010..The expression and biology of the tumor-associated antigen (TAA) 5T4 suggest it is an effective target for cancer immunotherapy... - Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trialRobert J Amato
Department of Genitourinary Oncology Program, The Methodist Hospital Research Institute, 6560 Fannin, Houston, TX 77047, USA
J Immunother 31:577-85. 2008..The high frequency of 5T4-specific immune responses and relationship with enhanced time to progression is encouraging and warrants further investigation... - Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III studyRobert J Amato
The University of Texas Memorial Hermann Hospital, Houston, TX, USA
Clin Cancer Res 16:5539-47. 2010.... - Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trialRobert J Amato
The Methodist Hospital Research Institute, Houston, Texas 77030, USA
Anticancer Drugs 19:527-33. 2008..27 (1.13-15.97) months and median overall survival (range) was 11.42+ (1.13-29.07+) months. Combination of gefitinib with interferon safely delays progression of refractory MRCC. Further studies in this setting are warranted... - A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancerRobert J Amato
Department of Internal Medicine, Division of Oncology, The University of Texas Health Medical School, Memorial Hermann Cancer Center, Houston, Texas 77030, USA
Cancer 115:2438-46. 2009..mTOR inhibitors and agents with primarily antiangiogenic activity have been shown to have efficacy in renal cell cancer (RCC). This phase 2 study assessed the efficacy of daily oral dosing with everolimus in patients with RCC... - A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancerRobert J Amato
The Methodist Hospital, The Methodist Hospital Research Institute, Houston, TX 77030, USA
Clin Genitourin Cancer 4:281-6. 2006..A phase I dose-escalation study was conducted to evaluate the use of these agents in combination to enhance the chemotherapeutic effects of treatment for refractory cancer... - Targeted anti-cancer therapies for renal cancerRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, Texas 77030, USA
Drugs 66:2161-71. 2006..On the basis of the limited studies to date, targeted therapies offer the greatest clinical benefit in the management of this malignancy, although additional basic research is still warranted to further improve clinical outcome... - Radiation therapy in the management of brain metastases from renal cell carcinomaLucius S Doh
Department of Radiology, Section of Radiation Oncology, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Oncology (Williston Park) 20:603-13; discussion 613, 616, 619-20 passsim. 2006..Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed... - The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trialL Cohen
Department of Behavioral Science, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Cancer 91:1949-55. 2001..The authors prospectively examined the association between treatment-specific optimism and mental health among patients participating in a Phase I/b trial... - Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trialS M Tu
Department of Genitourinary Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
Lancet 357:336-41. 2001..Prostate carcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted consolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate... - 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapyRobert J Amato
The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin, Suite 2050, Houston, Texas 77030, USA
Expert Opin Biol Ther 7:1463-9. 2007..With its minimal side effects and demonstrated ability to produce strong immune responses in patient populations, MVA-5T4 is a promising addition to the cancer therapy arsenal... - Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testisRobert J Amato
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
Urology 63:144-8; discussion 148-9. 2004..This approach may avoid potential problems with compliance and diminish the cost of scrupulous follow-up. Our results support that surveillance for carefully selected patients at a low risk of relapse is appropriate... - Therapeutic targets for metastatic prostate cancerTerry L Timme
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Curr Drug Targets 4:251-61. 2003.... - Metastatic renal cell carcinoma to the nose and ethmoid sinusMohammadbagher Ziari
Department of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA
Urology 67:199. 2006..The patient achieved a complete response both clinically and by magnetic resonance imaging, without any side effects. Late and rare sites of recurrences and treatment options are discussed... - Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapyRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
Clin Genitourin Cancer 5:422-6. 2007..Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest... - Vaccine therapy for renal cancerRobert J Amato
Genitourinary Oncology Program The Methodist Hospital Research Institute 6560 Fannin, Suite 2050, Houston, TX 77030, USA
Expert Rev Vaccines 7:925-35. 2008.... - Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasmsSteven S Shen
Department of Pathology, The Methodist Hospital, Baylor College of Medicine, Houston, TX 77030, USA
Mod Pathol 18:933-40. 2005..These results demonstrated high sensitivity and specificity of Ksp-cadherin for distal convoluted tubules, which can be used as adjunct for diagnosis of chromophobe RCC... - Heat-shock protein-peptide complex-96 for the treatment of cancerRobert J Amato
The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, Texas, USA
Expert Opin Biol Ther 7:1267-73. 2007..This paper reviews the development and clinical trial progress of vitespen, an HSP peptide complex vaccine based on tumor-derived glycoprotein 96... - Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumoursK Fizazi
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Br J Cancer 86:1555-60. 2002..Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients... - A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trialK Fizazi
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
Ann Oncol 13:125-34. 2002.... - Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the ProstateRobert J Amato
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX
Clin Med Oncol 2:471-5. 2008..5 to 10 months. These results indicate that further study of GM-CSF administration is not warranted for hormone-refractory patients but is recommended for hormone-naïve patients using a chronic dosing regimen... - Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccineLorenzo Cohen
Department of Behavioral Science, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 243, Houston, TX 77030, USA
Urol Oncol 7:119-24. 2002..We prospectively examined quality of life (QOL) in patients with metastatic renal cell carcinoma treated with nephrectomy followed by heat shock protein peptide complex 96 (HSPPC-96) vaccine, a nontoxic, active, specific immunotherapy... - Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancerRobert J Amato
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
Invest New Drugs 20:413-7. 2002..There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer... - Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumorsRonald E Fisher
Methodist Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
J Nucl Med 49:899-906. 2008.... - Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosisFederico A Monzon
Department of Pathology, The Methodist Hospital Research Institute, Houston, TX, USA
Mod Pathol 24:1470-9. 2011..Further exploration of 8q gain, 14q loss, MYC, HIF1A and EPAS1 (HIF2?) as molecular markers of tumor behavior and prognosis could aid in personalizing medicine for patients with clear-cell renal cell carcinoma... - The role of caveolin-1 in androgen insensitive prostate cancerVladimir Mouraviev
Scott Department of Urology, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
J Urol 168:1589-96. 2002..They show the potential for caveolin-1 as a biomarker therapeutic target for this important malignancy... - Endocrine levels at the start of treatment are associated with subsequent psychological adjustment in cancer patients with metastatic diseaseL Cohen
Department of Behavioral Science, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Psychosom Med 63:951-8. 2001..This study examined the association between hormonal profiles at the start of cancer treatment and subsequent psychological symptomatology... - The emerging role of the PI3-K-Akt pathway in prostate cancer progressionL Li
Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
Prostate Cancer Prostatic Dis 8:108-18. 2005.... - Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligandsWei He
Department of Chemistry, Purdue University, West Lafayette, IN 47906, USA
Int J Cancer 123:1968-73. 2008..Use of tumor-specific fluorescent ligands to label CTCs in peripheral blood can provide a simple, accurate and sensitive method for determining the number of cancer cells circulating in the bloodstream... - Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer CenterMingxin Che
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Cancer 95:1228-33. 2002.... - Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumorsKarim Fizazi
Genito Urinary Group of the French Federation of Cancer Centers, Paris, France
J Clin Oncol 22:3868-76. 2004.... - Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsClaude Sportes
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
J Exp Med 205:1701-14. 2008....